Physician profile
Michael Tavdy
NPI 1720016793
$19,372.93
in general payments reported to CMS, 2019-2025
55 companies · $2,556 in 2025
The $2,556 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,675 · 2020: $1,758 · 2021: $2,880 · 2022: $2,840 · 2023: $2,605 · 2024: $3,059 · 2025: $2,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,150 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,150.30 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,391.06 | 2019-2025 | Ubrelvy, Linzess, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,028.19 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $1,206.58 | 2019-2025 | Evenity, Krystexxa, Otezla |
| Astrazeneca Pharmaceuticals LP | $993.42 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $975.29 | 2019-2023 | |
| Novo Nordisk INC | $960.90 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $604.42 | 2022-2025 | |
| Scilex Pharmaceuticals INC. | $582.62 | 2019-2025 | Ztlido |
| Astellas Pharma US INC | $557.55 | 2019-2025 | Veozah |
| Lilly USA, LLC | $548.24 | 2019-2025 | Mounjaro, Zepbound |
| Amneal Pharmaceuticals LLC | $545.04 | 2021-2024 | Unithroid |
| Glaxosmithkline, LLC. | $525.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $459.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $425.05 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $417.42 | 2019-2024 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tavdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.